Literature DB >> 25898160

The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.

Lowell J Brady1, Jyoti Velayudhan, Devi B Visone, Ken C Daugherty, Jeff L Bartron, Michael Coon, Cabot Cornwall, Peter J Hinckley, Lisa Connell-Crowley.   

Abstract

Accurate measurement and functional characterization of antibody Fc domain N-linked glycans is critical to successful biosimilar development. Here, we describe the application of methods to accurately quantify and characterize the N-linked glycans of 2 IgG1 biosimilars with effector function activity, and show the potential pitfalls of using assays with insufficient resolution. Accurate glycan assessment was combined with glycan enrichment using lectin chromatography or production with glycosylation inhibitors to produce enriched pools of key glycan species for subsequent assessment in cell-based antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity effector function assays. This work highlights the challenges of developing high-quality biosimilar candidates and the need for modern biotechnology capabilities. These results show that high-quality analytics, combined with sensitive cell-based assays to study in vivo mechanisms of action, is an essential part of biosimilar development.

Entities:  

Keywords:  ACN, acetonitrile; ADCC; ADCC, antibody-dependent cell-mediated cytotoxicity; AHGs, afucosylated hybrid glycans; AMBGs, afucosylated monoantennary and biantennary glycans; BGGs, β-galactosylated glycans; CDC; CDC, complement-dependent cytotoxicity; CHO, Chinese hamster ovary; CQA, critical quality attribute; Con A, concanavalin A lectin; EIC, extracted ion current; FT, flow-through; Fc domain; HC, heavy chain; HGs, hybrid glycans; HILIC, hydrophilic interaction liquid chromatography; HMGs, high-mannose glycans; HPLC, high performance liquid chromatography; LC, light chain; MS, mass spectrometry; MS/MS, tandem mass spectrometry; N-linked carbohydrates; PQA, product quality attribute; SGs, sialylated glycans; SM, starting material; TRIS, tris(hydroxymethyl)aminomethane; antibody; biosimilar; effector function; glycosylation; mAb; mAb, monoclonal antibody

Mesh:

Substances:

Year:  2015        PMID: 25898160      PMCID: PMC4622562          DOI: 10.1080/19420862.2015.1016692

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  27 in total

1.  Identification of multiple sources of charge heterogeneity in a recombinant antibody.

Authors:  R J Harris; B Kabakoff; F D Macchi; F J Shen; M Kwong; J D Andya; S J Shire; N Bjork; K Totpal; A B Chen
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-03-10

2.  Contrasting IgG structures reveal extreme asymmetry and flexibility.

Authors:  Erica Ollmann Saphire; Robyn L Stanfield; M D Max Crispin; Paul W H I Parren; Pauline M Rudd; Raymond A Dwek; Dennis R Burton; Ian A Wilson
Journal:  J Mol Biol       Date:  2002-05-24       Impact factor: 5.469

3.  Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.

Authors:  Jason Hodoniczky; Yuan Zhi Zheng; David C James
Journal:  Biotechnol Prog       Date:  2005 Nov-Dec

4.  Engineered antibody Fc variants with enhanced effector function.

Authors:  Greg A Lazar; Wei Dang; Sher Karki; Omid Vafa; Judy S Peng; Linus Hyun; Cheryl Chan; Helen S Chung; Araz Eivazi; Sean C Yoder; Jost Vielmetter; David F Carmichael; Robert J Hayes; Bassil I Dahiyat
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

5.  IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.

Authors:  Rinpei Niwa; Akito Natsume; Aya Uehara; Masako Wakitani; Shigeru Iida; Kazuhisa Uchida; Mitsuo Satoh; Kenya Shitara
Journal:  J Immunol Methods       Date:  2005-09-22       Impact factor: 2.303

6.  Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity.

Authors:  B M Kumpel; T W Rademacher; G A Rook; P J Williams; I B Wilson
Journal:  Hum Antibodies Hybridomas       Date:  1994

7.  Humanization of an anti-p185HER2 antibody for human cancer therapy.

Authors:  P Carter; L Presta; C M Gorman; J B Ridgway; D Henner; W L Wong; A M Rowland; C Kotts; M E Carver; H M Shepard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

8.  Construction and initial characterization of a mouse-human chimeric anti-TNF antibody.

Authors:  D M Knight; H Trinh; J Le; S Siegel; D Shealy; M McDonough; B Scallon; M A Moore; J Vilcek; P Daddona
Journal:  Mol Immunol       Date:  1993-11       Impact factor: 4.407

9.  Increased concanavalin A-binding capacity of immunoglobulin G purified from sera of patients with rheumatoid arthritis.

Authors:  M G Malaise; P Franchimont; C Bouillene; C Houssier; P R Mahieu
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

10.  Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.

Authors:  A Wright; S L Morrison
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  7 in total

1.  Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics.

Authors:  Richard S Rogers; Nancy S Nightlinger; Brittney Livingston; Phil Campbell; Robert Bailey; Alain Balland
Journal:  MAbs       Date:  2015-07-17       Impact factor: 5.857

2.  The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor.

Authors:  Ganesh P Subedi; Adam W Barb
Journal:  MAbs       Date:  2016-08-05       Impact factor: 5.857

3.  Low prevalence of rheumatoid arthritis among patients with pre-existing type 2 diabetes mellitus.

Authors:  Anastasios Tentolouris; Anastasia Thanopoulou; Nikolaos Tentolouris; Ioanna Eleftheriadou; Christina Voulgari; Alexandros Andrianakos; Petros P Sfikakis
Journal:  Ann Transl Med       Date:  2018-10

4.  Galactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA Associated Vasculitis.

Authors:  Michael J Kemna; Rosina Plomp; Pieter van Paassen; Carolien A M Koeleman; Bas C Jansen; Jan G M C Damoiseaux; Jan Willem Cohen Tervaert; Manfred Wuhrer
Journal:  EBioMedicine       Date:  2017-01-28       Impact factor: 8.143

5.  Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors Reveals Similar IgG Fc Glycoform Preferences to Human Receptors.

Authors:  Andrew R Crowley; Nana Yaw Osei-Owusu; Gillian Dekkers; Wenda Gao; Manfred Wuhrer; Diogo M Magnani; Keith A Reimann; Seth H Pincus; Gestur Vidarsson; Margaret E Ackerman
Journal:  Front Immunol       Date:  2021-10-12       Impact factor: 7.561

Review 6.  Posttranslational Modifications and the Immunogenicity of Biotherapeutics.

Authors:  Roy Jefferis
Journal:  J Immunol Res       Date:  2016-04-14       Impact factor: 4.818

Review 7.  Complement in the Initiation and Evolution of Rheumatoid Arthritis.

Authors:  V Michael Holers; Nirmal K Banda
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.